Comparison of the interaction of uridine, cytidine, and other pyrimidine nucleoside analogues with recombinant human equilibrative nucleoside transporter 2 (hENT2) produced in<i>Saccharomyces cerevisiae</i>

Biochemistry and Cell Biology - Tập 80 Số 5 - Trang 639-644 - 2002
Mark F. Vickers1, Rakesh Kumar, Frank Visser, Jing Zhang, Jahangir Charania, R. Taylor Raborn, Stephen A. Baldwin, James D. Young, Carol E. Cass
1Department of Oncology, University of Alberta & Cross Cancer Institute, Edmonton, Canada

Tóm tắt

The human equilibrative nucleoside transporters 1 and 2 (hENT1, hENT2) share 50% amino acid identity and exhibit broad selectivities, accepting purine and pyrimidine nucleosides as permeants. The permeant selectivity of hENT2 is less well understood because of the low abundance of the native transporter in cells amenable to functional analysis. Recent studies of hENT2 produced in recombinant form in functional expression systems have shown that it differs from hENT1 in that it transports nucleobases. To further understand the structural requirements for permeant interaction with hENT2, we compared the relative abilities of uridine, cytidine, and their analogues to inhibit transport of [3H]uridine by recombinant hENT1 and hENT2 produced in yeast. hENT1 and hENT2 tolerated halogen modification at the 5 position of the base and the 2' and 5' positions of the ribose moieties of uridine whereas removal of the hydroxyl group at the 3' position of the ribose moiety of uridine eliminated interaction with both transporters. hENT2 displayed a lower ability, compared with hENT1, to interact with cytidine and cytidine analogues, suggesting a low tolerance for the presence of the amino group at the 4 position of the base.Key words: hENT2, hENT1, araC, uridine, NBMPR.

Từ khóa


Tài liệu tham khảo

Brunelli J.P., 1993, Yeast, 9, 1299, 10.1002/yea.320091203

Cass C.E., 1972, J. Biol. Chem., 247, 3314, 10.1016/S0021-9258(19)45247-2

Cass C.E., 1973, Biochim. Biophys. Acta, 291, 734, 10.1016/0005-2736(73)90477-X

Cass C.E., 1998, Biochem. Cell Biol., 76, 761, 10.1139/o98-095

Crawford C.R., 1998, J. Biol. Chem., 273, 5288, 10.1074/jbc.273.9.5288

Griffith D.A., 1996, Biochim. Biophys. Acta, 1286, 153, 10.1016/S0304-4157(96)00008-1

Griffiths M., 1997, Nat. Med., 3, 89, 10.1038/nm0197-89

Griffiths M., 1997, Biochem. J., 328, 739, 10.1042/bj3280739

Ito H., 1983, J. Bacteriol., 153, 163, 10.1128/JB.153.1.163-168.1983

Janmohamed N.S., 1985, Biochem. J., 230, 777, 10.1042/bj2300777

Jarvis S.M., 1986, Biochem. J., 233, 295, 10.1042/bj2330295

Jennings L.L., 2001, Neuropharmacology, 40, 722, 10.1016/S0028-3908(00)00207-0

Kumar R., 1994, Can. J. Chem., 72, 2005, 10.1139/v94-256

Kumar R., 1996, Nucleosides Nucleotides, 15, 265, 10.1080/07328319608002384

Mackey J.R., 1998, Drug Resist. Updates, 1, 310, 10.1016/S1368-7646(98)80047-2

Mackey J.R., 1999, J. Natl. Cancer Inst., 91, 1876, 10.1093/jnci/91.21.1876

Pennycooke M., 2001, Biochem. Biophys. Res. Commun., 280, 951, 10.1006/bbrc.2000.4205

SenGupta D.J., 2002, Biochemistry, 41, 1512, 10.1021/bi015833w

Sundaram M., 2001, J. Biol. Chem., 276, 270, 10.1074/jbc.M107169200

Tse C.M., 1985, J. Biol. Chem., 260, 3506, 10.1016/S0021-9258(19)83651-7

Vickers M.F., 1999, Biochem. J., 339, 21, 10.1042/bj3390021

Vickers M.F., 2000, J. Biol. Chem., 275, 931, 10.1074/jbc.M000239200

Vickers M.F., 2000, Emerging Ther. Targets, 4, 515, 10.1517/14728222.4.4.515

Vickers M.F., 2001, Mol. Membr. Biol., 18, 73, 10.1080/09687680010033306

Visser F., 2002, J. Biol. Chem., 277, 395, 10.1074/jbc.M105324200

Ward J.L., 2000, J. Biol. Chem., 275, 8375, 10.1074/jbc.275.12.8375

Yao S.Y., 2002, J. Biol. Chem., 277, 938

Zimmerman T.P., 1987, J. Biol. Chem., 262, 5748, 10.1016/S0021-9258(18)45638-4

Thông tin
Thông tin xuất bản

Biochemistry and Cell Biology

Tập 80 Số 5

639-644

Thông tin tác giả